Literature DB >> 16465866

[Concepts in hemophilia treatment].

Monika Barthels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16465866      PMCID： PMC7168056          DOI： 10.1002/pauz.200500155

Source DB:  PubMed          Journal:  Pharm Unserer Zeit        ISSN： 0048-3664


× No keyword cloud information.
  10 in total

Review 1.  Virus safety of prothrombin complex concentrates and factor IX concentrates.

Authors:  R Seitz; J Dodt
Journal:  Thromb Res       Date:  1999-08-15       Impact factor: 3.944

2.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

Review 3.  The hemophilias--from royal genes to gene therapy.

Authors:  P M Mannucci; E G Tuddenham
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

Review 4.  Therapeutic choices for patients with hemophilia and high-titer inhibitors.

Authors:  R Kulkarni; L M Aledort; E Berntorp; H H Brackman; D Brown; A R Cohen; N P Ewing; A Gringeri; R Gruppo; K Hoots; C Leissenger; K Peerlinck; M C Poon; W Y Wong
Journal:  Am J Hematol       Date:  2001-08       Impact factor: 10.047

Review 5.  [Clotting factor concentrates].

Authors:  M Barthels; W Schramm
Journal:  Hamostaseologie       Date:  2004-11       Impact factor: 1.778

6.  Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

Authors:  H H Brackmann; J Oldenburg; R Schwaab
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

7.  [Rules and regulations in the therapy of hemophilia].

Authors:  G Landbeck; A Kurme
Journal:  Fortschr Med       Date:  1972-05-11

Review 8.  [Congenital deficiencies of coagulation factors and acquired inhibitors leading to bleeding disorders].

Authors:  E O Meili
Journal:  Hamostaseologie       Date:  2004-11       Impact factor: 1.778

Review 9.  [Classification of von Willebrand disease].

Authors:  R Schneppenheim; U Budde
Journal:  Hamostaseologie       Date:  2004-02       Impact factor: 1.778

10.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

Authors:  I M Nilsson; E Berntorp; O Zettervall
Journal:  N Engl J Med       Date:  1988-04-14       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.